Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.53 |
| ▸ | ENPP1 | P22413 | 16/20 | 0.43 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23326745 | 0.78 | ENPP1 (0.44) | PDE3BPDE3AENPP1ENPP3 | |
| SCHEMBL30556397 | 0.78 | ENPP1 (0.42) | PDE3BPDE3AENPP1ENPP3 | |
| SCHEMBL24671871 | 0.78 | ENPP1 (0.42) | PDE3BPDE3AENPP1ENPP3 | |
| SCHEMBL4184377 | 0.77 | ENPP1 (0.43) | PDE3BPDE3AENPP1ENPP3 | |
| SCHEMBL12775783 | 0.77 | PDE3B (0.57) | PDE3BPDE3AENPP1ENPP3 | |
| SCHEMBL12776683 | 0.75 | PDE3B (0.58) | PDE3BPDE3AENPP1ENPP3 | |
| SCHEMBL12775794 | 0.74 | PDE3B (0.59) | PDE3BPDE3AENPP1ENPP3ADORA1 | |
| SCHEMBL8805431 | 0.73 | PDE3B (0.44) | PDE3BPDE3AADORA1 | |
| SCHEMBL5676640 | 0.73 | PDE3B (0.53) | PDE3BPDE3A | |
| SCHEMBL30857513 | 0.73 | PDE3B (0.33) | PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140302012-A1 | Combination Therapies for Treating Hematologic Malignancies Using Pyridopyrimidinone Inhibitors of PI3K/mTOR with Bendamustine and/or Rituximab | SANOFI (FR) | 2014-10-09 | — | — | US | disclosed |
| EP-2074122-B9 | PYRIDO (2, 3-D) PYRIMIDIN0NE COMPOUNDS AND THEIR USE AS PI3 INHIBITORS | PFIZER PROD INC (US) | 2013-09-11 | — | — | EP | disclosed |
| EP-2074122-B1 | PYRIDO (2, 3-D) PYRIMIDIN0NE COMPOUNDS AND THEIR USE AS PI3 INHIBITORS | PFIZER PROD INC (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20110059976-A1 | PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2011-03-10 | — | — | US | disclosed |
| US-7767687-B2 | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors | BIOGEN IDEC MA INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-7696213-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080090801-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090801-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PI4KA, PI4KB, PIK3CA | PDE3B 760/4885PDE3A 1023/4885ENPP1 1000/4885 |
| US-20140302012-A1 | Combination Therapies for Treating Hematologic Malignancies Using Pyridopyrimidinone Inhibitors of PI3K/mTOR with Bendamustine and/or Rituximab | BTK, MTOR, BCL6 | PDE3B 782/4885PDE3A 1279/4885ENPP1 922/4885 |
| US-20110059976-A1 | PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | PDE3B 1744/4885PDE3A 1801/4885ENPP1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.